Pioneer in phage-based diagnostics

01359 231856

Twitter Youtube Linkedin Envelope
  • Home
  • About
    • About PBD Biotech
    • Leadership
    • Blog
  • Latest
    • Press releases
    • In the news
    • Events
  • Actiphage TB
    • What is Actiphage TB?
    • Phage-based diagnostics
    • Unique role in TB testing
    • Supporting test and treat campaigns
    • Clinical studies
  • Lab Support
    • Laboratory Support
    • Solutions for laboratory developed tests
    • Actiphage assay workflow
    • Instructions for use of Actiphage
  • TB Drug Research
    • TB drug research
    • Research Use Only
    • Biomarker for TB prevention
  • Contact
    • Contacting us
    • Partnerships and collaborations
Menu
  • Home
  • About
    • About PBD Biotech
    • Leadership
    • Blog
  • Latest
    • Press releases
    • In the news
    • Events
  • Actiphage TB
    • What is Actiphage TB?
    • Phage-based diagnostics
    • Unique role in TB testing
    • Supporting test and treat campaigns
    • Clinical studies
  • Lab Support
    • Laboratory Support
    • Solutions for laboratory developed tests
    • Actiphage assay workflow
    • Instructions for use of Actiphage
  • TB Drug Research
    • TB drug research
    • Research Use Only
    • Biomarker for TB prevention
  • Contact
    • Contacting us
    • Partnerships and collaborations

Actiphage TB

Diagnostic tests that are able to predict the development of TB are urgently needed (WHO, 2017). In clinical studies, Actiphage technology detected active TB in LTBI patients (incipient TB) and may predict progression from infection to active TB, meeting the needs of the WHO target product profile for an incipient TB test.

Actiphage TB uniquely detects active TB

Tuberculosis is the world’s most fatal infectious disease, and it can lay dormant in an infected individual until their immune system is compromised by another infection, stress or malnutrition. The Actiphage TB test is able to detect the pathogen Mycobacterium tuberculosis (Mtb) in a blood sample when it escapes the body’s immune system, offering potential for a biomarker of disease progression.

Actiphage TB:

  • the only blood-based test that combines phage technology, to detect only active, disease-causing mycobacteria, with traditional qPCR methods.
  • leverages phage-based technology that is unique and detects only active TB bacterial cells, inherently leading to the higher specificity than other diagnostic methods.
  • is a new, innovative TB diagnostic, is being developed as an incipient TB test and may allow for the scale-up of test-and-treat campaigns.
  • may play roles in TB screening across the continuum of TB infection and management of TB drug therapy.

In the fight to End TB, Actiphage TB has potential to detect those with progressive disease. Also to monitor the efficacy of drug treatment – a test of cure – something that is not possible with current technology.

What is Actiphage?
Actiphage clinical studies
Actiphage clinical studies
Actiphage’s unique role in TB testing
Think Test Treat CDC
Actiphage supports test and treat campaigns
PBD Biotech in the news
PBD Biotech in the news
Contact us
Find out more

Actiphage has not received market clearance status by the U.S FDA or any other country’s regulatory authority.

Contact Us

General contact form

Name(Required)
Location

developers of phage-based diagnostics

Contact Us

Registered Company Address
Grosvenor St Paul’s
Grosvenor House
11 St Paul’s Square
Birmingham
B3 1RB
United Kingdom

T: 01359 231856
info@pbdbio.com

BIVDA member 2023
Twitter Youtube Linkedin

Privacy and cookies policy

© 2022 PBD Biotech Ltd

design: out of house